Cargando…
Clinical application of a modified predeposit autologous red blood cell apheresis in multistage spinal fusion: a single-center retrospective study
PURPOSE: This study aimed to evaluate the efficacy and safety of predeposit autologous RBC apheresis (PARA) in patients undergoing multilevel spinal fusion surgery. METHODS: A total of 112 patients from January 2020 to June 2022 were divided into two groups according to PARA: the PARA group (n = 51)...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225601/ https://www.ncbi.nlm.nih.gov/pubmed/37256088 http://dx.doi.org/10.3389/fmed.2023.1149093 |
_version_ | 1785050409871605760 |
---|---|
author | Xu, Xiao-Ping Que, Wen-Jun Yu, Ze-Bo Shen, Jie-Liang Hu, Zhen-Ming Yang, Xiao-Liang Hao, Jie |
author_facet | Xu, Xiao-Ping Que, Wen-Jun Yu, Ze-Bo Shen, Jie-Liang Hu, Zhen-Ming Yang, Xiao-Liang Hao, Jie |
author_sort | Xu, Xiao-Ping |
collection | PubMed |
description | PURPOSE: This study aimed to evaluate the efficacy and safety of predeposit autologous RBC apheresis (PARA) in patients undergoing multilevel spinal fusion surgery. METHODS: A total of 112 patients from January 2020 to June 2022 were divided into two groups according to PARA: the PARA group (n = 51) and the control group (n = 61). The baseline characteristics of the patients, outcomes, transfusion cost, hospitalization cost, length of stay, complications, and changes in hemoglobin and hematocrit levels between the two groups were compared. RESULTS: The baseline characteristics were similar in both groups. No significant differences were found in functional outcomes, including VAS score (p = 0.159), ODI score (p = 0.214), JOA score (p = 0.752), and SF-36 score (p = 0.188) between the PARA and control groups. The amount and rate of intraoperative and perioperative allogeneic RBC transfusion were significantly higher in the control group than in the PARA group (p < 0.001). The postoperative (9.04 ± 3.21 vs. 11.05 ± 3.84, p = 0.004) and total length of stay (15.78 ± 3.79 vs. 17.36 ± 4.08, p = 0.038) in the PARA group were significantly lower than those in the control group, respectively. Despite no difference in hospitalization cost (p = 0.737), the total blood transfusion cost in the PARA group was significantly lower, compared with the control group (p < 0.001). For safety evaluation, there were no significant differences in Hb and Hct levels between the two groups at admission, on postoperative day 1, and postoperative day 3, respectively (p > 0.05). Moreover, the number of postoperative infections in the PARA group was significantly lower than that in the control group (p = 0.038). CONCLUSION: PARA was a novel, safe, and highly efficient technique for mass autologous blood preparation in a quite short preparation time. This method could significantly reduce the amount of allogeneic blood transfusion and length of stay, which could provide a theoretical basis for following clinical practice about the technique. |
format | Online Article Text |
id | pubmed-10225601 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102256012023-05-30 Clinical application of a modified predeposit autologous red blood cell apheresis in multistage spinal fusion: a single-center retrospective study Xu, Xiao-Ping Que, Wen-Jun Yu, Ze-Bo Shen, Jie-Liang Hu, Zhen-Ming Yang, Xiao-Liang Hao, Jie Front Med (Lausanne) Medicine PURPOSE: This study aimed to evaluate the efficacy and safety of predeposit autologous RBC apheresis (PARA) in patients undergoing multilevel spinal fusion surgery. METHODS: A total of 112 patients from January 2020 to June 2022 were divided into two groups according to PARA: the PARA group (n = 51) and the control group (n = 61). The baseline characteristics of the patients, outcomes, transfusion cost, hospitalization cost, length of stay, complications, and changes in hemoglobin and hematocrit levels between the two groups were compared. RESULTS: The baseline characteristics were similar in both groups. No significant differences were found in functional outcomes, including VAS score (p = 0.159), ODI score (p = 0.214), JOA score (p = 0.752), and SF-36 score (p = 0.188) between the PARA and control groups. The amount and rate of intraoperative and perioperative allogeneic RBC transfusion were significantly higher in the control group than in the PARA group (p < 0.001). The postoperative (9.04 ± 3.21 vs. 11.05 ± 3.84, p = 0.004) and total length of stay (15.78 ± 3.79 vs. 17.36 ± 4.08, p = 0.038) in the PARA group were significantly lower than those in the control group, respectively. Despite no difference in hospitalization cost (p = 0.737), the total blood transfusion cost in the PARA group was significantly lower, compared with the control group (p < 0.001). For safety evaluation, there were no significant differences in Hb and Hct levels between the two groups at admission, on postoperative day 1, and postoperative day 3, respectively (p > 0.05). Moreover, the number of postoperative infections in the PARA group was significantly lower than that in the control group (p = 0.038). CONCLUSION: PARA was a novel, safe, and highly efficient technique for mass autologous blood preparation in a quite short preparation time. This method could significantly reduce the amount of allogeneic blood transfusion and length of stay, which could provide a theoretical basis for following clinical practice about the technique. Frontiers Media S.A. 2023-05-15 /pmc/articles/PMC10225601/ /pubmed/37256088 http://dx.doi.org/10.3389/fmed.2023.1149093 Text en Copyright © 2023 Xu, Que, Yu, Shen, Hu, Yang and Hao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Xu, Xiao-Ping Que, Wen-Jun Yu, Ze-Bo Shen, Jie-Liang Hu, Zhen-Ming Yang, Xiao-Liang Hao, Jie Clinical application of a modified predeposit autologous red blood cell apheresis in multistage spinal fusion: a single-center retrospective study |
title | Clinical application of a modified predeposit autologous red blood cell apheresis in multistage spinal fusion: a single-center retrospective study |
title_full | Clinical application of a modified predeposit autologous red blood cell apheresis in multistage spinal fusion: a single-center retrospective study |
title_fullStr | Clinical application of a modified predeposit autologous red blood cell apheresis in multistage spinal fusion: a single-center retrospective study |
title_full_unstemmed | Clinical application of a modified predeposit autologous red blood cell apheresis in multistage spinal fusion: a single-center retrospective study |
title_short | Clinical application of a modified predeposit autologous red blood cell apheresis in multistage spinal fusion: a single-center retrospective study |
title_sort | clinical application of a modified predeposit autologous red blood cell apheresis in multistage spinal fusion: a single-center retrospective study |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225601/ https://www.ncbi.nlm.nih.gov/pubmed/37256088 http://dx.doi.org/10.3389/fmed.2023.1149093 |
work_keys_str_mv | AT xuxiaoping clinicalapplicationofamodifiedpredepositautologousredbloodcellapheresisinmultistagespinalfusionasinglecenterretrospectivestudy AT quewenjun clinicalapplicationofamodifiedpredepositautologousredbloodcellapheresisinmultistagespinalfusionasinglecenterretrospectivestudy AT yuzebo clinicalapplicationofamodifiedpredepositautologousredbloodcellapheresisinmultistagespinalfusionasinglecenterretrospectivestudy AT shenjieliang clinicalapplicationofamodifiedpredepositautologousredbloodcellapheresisinmultistagespinalfusionasinglecenterretrospectivestudy AT huzhenming clinicalapplicationofamodifiedpredepositautologousredbloodcellapheresisinmultistagespinalfusionasinglecenterretrospectivestudy AT yangxiaoliang clinicalapplicationofamodifiedpredepositautologousredbloodcellapheresisinmultistagespinalfusionasinglecenterretrospectivestudy AT haojie clinicalapplicationofamodifiedpredepositautologousredbloodcellapheresisinmultistagespinalfusionasinglecenterretrospectivestudy |